PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 2001 May; 94(5): 238–240.
PMCID: PMC1281457

Partial lipodystrophy, polycystic ovary syndrome and proteinuria: a common link to insulin resistance?

V C Blackwell, MRCP, P Salis, MD,1 R W Groves, FRCP, S E Baldeweg, MRCP,2 G S Conway, FRCP,2 and R J Unwin, FRCP1

Insulin resistance is emerging as a key, and possibly primary, abnormality in a variety of seemingly unrelated diseases1.

CASE HISTORY

A Caucasian woman aged 30 was referred because of uncontrolled hypertension and proteinuria. She had a 4-year history of insulin-requiring diabetes mellitus, which was difficult to control; she was taking cyproterone acetate and ethinyloestradiol for infertility attributed to polycystic ovary syndrome (PCOS). Over the preceding 5 years she had noticed a gradual change in her appearance, with her face, hands and feet becoming thinner. On examination, there was striking loss of the subcutaneous fat from her cheeks and limbs, with increased fat deposition under her chin and over her upper back (Figure 1 a,Figure 1 b,Figure 1 c). She also had androgenic alopecia with facial hirsutism and minimal breast development, as well as peripheral acrocyanosis; she complained of severe Raynaud's phenomenon. Her blood pressure was 188/114 mmHg lying and 194/120 mmHg standing; she had heavy proteinuria (6.1 g/24 h) but no peripheral oedema; plasma albumin concentration was normal. Plasma urea and electrolytes, creatinine clearance, serum complement and immunoglobulins, and an autoantibody screen all gave normal results. When exogenous insulin was withheld, basal plasma insulin concentration was 906 pmol/L (normal range 11-86)—a finding consistent with underlying insulin resistance. Serum trigylceride concentration ranged between 3 and 5 mmol/L (normal < 1.8) and her total cholesterol was between 5 and 6 mmol/L (ideal < 5.2). An ultrasound scan of her abdomen showed kidneys of normal size and texture but fatty infiltration of the liver (which is commonly associated with insulin resistance). Renal artery stenosis as a cause of her hypertension was excluded by magnetic resonance angiography. Because of her heavy proteinuria in the absence of diabetic retinopathy or neuropathy, and the lack of improvement on lowering of blood pressure, she underwent renal biopsy. There were no features of diabetic renal disease; rather, the appearance was typical of focal and segmental glomerulosclerosis (FSGS) (Figure 2) without immune complex deposition (except in scarred areas due to ‘trapping’ of immunoglobulins): electron microscopy revealed foot process fusion, a feature of this condition. A skin biopsy taken from her forearm showed normal epidermis and dermis but complete absence of subcutaneous fat.

Figure (1a)
Clinical appearance. Androgenic alopecia, facial hirsutism, increased fat deposition under chin;
Figure (1b)
Clinical appearance. increased fat deposition on upper back;
Figure (1c)
Clinical appearance. loss of subcutaneous fat at extremities
Figure 2
Glomerular histology. Focal areas of segmental glomerulosclerosis can be seen at 11 o'clock. Periodic acid—Schiff × 400 original magnification

COMMENT

Lipodystrophy may be partial or total2. The patient we describe has partial lipodystrophy, which may be familial (autosomal dominant) or sporadic3. In the sporadic form, females are more frequently affected than males and subcutaneous fat is progressively lost from the upper body and face. The aetiology of the lipodystrophies is unknown. The partial form has been found in various other disorders, some autoimmune4,5,6. All forms of lipodystrophy are associated with insulin resistance and dyslipidaemia; other common features include hirsutism, acanthosis nigricans, menstrual abnormalities and PCOS7. Indeed, primary insulin resistance is now thought to underlie isolated PCOS and associated hyperandrogenism8.

There is a recognized association between partial lipodystrophy and a particular form of renal disease known as type II mesangiocapillary glomerulonephritis (MCGN)9. It is due to abnormal complement activation and C3 consumption triggered by an autoantibody, ‘C3 nephritic factor’, which may also be the cause of adipocyte loss by cell lysis10,11. Partial lipodystrophy almost always precedes the development of MCGN10, which can be precipitated by pregnancy or the contraceptive pill12. Unusually, our patient has FSGS and not MCGN (moreover she did not have detectable C3-nephritic factor). FSGS may be primary, and of unknown aetiology, or secondary to focal renal injury and scarring, resulting in reduced nephron mass and hyperfiltration (which also occurs in insulin-dependent diabetes, morbid obesity with insulin resistance and metabolic syndrome X)13. Renography in our patient did not reveal any cortical scarring.

An acquired form of partial lipodystrophy, again with insulin resistance, is that due to HIV protease inhibitors such as indinavir14. The mechanism is unknown, but the insulin resistance is thought to be primary and a cause, rather than a consequence, of adipocyte loss and redistribution. Moreover, there is evidence that these drugs directly inhibit the uptake of glucose by insulin-sensitive tissues such as fat and skeletal muscle15. HIV nephropathy can resemble (especially in those of African origin) FSGS, which may improve on protease inhibitor therapy16; but this only serves to underline the currently descriptive nature of this ill-understood form of glomerular injury. The inherited forms of lipodystrophy are not associated with mutations of candidate genes for insulin resistance such as those for the insulin receptor and adipocyte determination factor PPARγ17. Recent studies have localized the defect to chromosome 13 and a positional cloning approach has disclosed mutations in the gene encoding the nuclear envelope protein lamin A/C18, the function of which remains speculative. Interestingly, heterozygotes for one reported mutation are more likely than those with no mutation to have hypertension, dyslipidaemia and insulin resistance19.

Our patient exemplifies the variety of clinical and metabolic consequences that can be linked to insulin resistance and the importance of targeting therapy at this underlying defect. Indeed, since we began trying to reduce insulin resistance with metformin and rosiglitazone, her lipodystrophy has improved. This case highlights the need for a multidisciplinary approach to insulin resistance in all its guises and the importance of studies to determine: (1) adipocyte function and its relationship to insulin resistance; (2) the significance of lamin A/C mutations and normal adipocyte function; and (3) the role of insulin resistance per se in the pathogenesis of FSGS.

Acknowledgments

We thank Dr M Griffiths for reporting the renal histology and for providing Figure 2.

References

1. Walker M. Insulin resistance; a problem for clinicians and scientists. Diabet Med 2000;17: 406-8 [PubMed]
2. Black M, Cunliffe W. Subcutaneous fat: lipodystrophy. In: Champion R, Burton J, Burns D, Breathnach S, eds. Textbook of Dermatology. Oxford: Blackwell Scientific, 1998; 2426-32
3. Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nature Genet 1998;18: 292-5 [PubMed]
4. Wilson WA, Sissons JG, Morgan OS. Multiple autoimmune diseases with bilateral optic atrophy and lipodystrophy. Ann Intern Med 1978;89: 72-3 [PubMed]
5. Walport MJ, Davies KA, Botto M, et al. C3 nephritic factor and SLE: report of four cases and review of the literature. Q J Med 1994;87: 609-15 [PubMed]
6. Alarcon-Segovia D, Ramos-Niembro F. Association of partial lipodystrophy and Sjögren's syndrome [letter]. Ann Intern Med 1976;85: 474-5 [PubMed]
7. Piscatelli RL, Vieweg WV, Havel RJ. Partial lipodystrophy. Metabolic studies in three patients. Ann Intern Med 1970;73: 963-70 [PubMed]
8. Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998;145: 103-10 [PubMed]
9. Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med 1972;41: 343-54 [PubMed]
10. Levy Y, George J, Yona E, Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res 1998;18: 55-60 [PubMed]
11. Mathieson PW, Wurzner R, Oliveria DB, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993;177: 1827-31 [PMC free article] [PubMed]
12. Demetriou K, Kallikas I, Zouvani I, Kyriacou K, Pierides A. The pregnant patient with partial lipodystrophy developing acute renal failure—onset of de novo membranoproliferative glomerulonephritis. Nephrol Dial Transplant 1998;13: 2121-4 [PubMed]
13. Cameron JS. The enigma of focal segmental glomerulosclerosis. Kidney Int 1996;57(suppl): S119-S131 [PubMed]
14. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyper-lipidaemia, and insulin resistance. Lancet 1998;351: 1881-3 [PubMed]
15. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275: 20251-4 [PubMed]
16. Dellow E, Unwin RJ, Miller RF, Williams IA, Griffiths MH. Protease inhibitor therapy for HIV infection: the effect on HIV-associated nephrotic syndrome. Nephrol Dial Transplant 1999;14: 744-7 [PubMed]
17. Flier JS. Pushing the envelope on lipodystrophy. Nature Genet 2000;24: 103-4 [PubMed]
18. Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genet 2000;24: 153-6 [PubMed]
19. Hegele RA, Anderson CM, Wang J, Jones DC, Cao H. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res 2000;10: 652-8 [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press